Trials / Completed
CompletedNCT01003015
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
An Uncontrolled Open Label Multicenter Phase II Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY73-4506 | 160 mg BAY73-4506 |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-11-01
- Completion
- 2013-03-01
- First posted
- 2009-10-28
- Last updated
- 2015-04-03
Locations
13 sites across 4 countries: Germany, Italy, South Korea, Spain
Source: ClinicalTrials.gov record NCT01003015. Inclusion in this directory is not an endorsement.